Emilsson H
Department of Pharmacy, Karolinska Institute, Huddinge Hospital, Sweden.
J Chromatogr. 1987 Oct 30;421(2):319-26. doi: 10.1016/0378-4347(87)80411-5.
A sensitive and selective high-performance liquid chromatographic method for determination of intact glipizide in human plasma or urine has been developed. The plasma and urine samples were acid-buffered, before tolbutamide was added as internal standard. The samples were extracted with benzene, and the organic layer was evaporated to dryness. The residue was dissolved in equilibrated mobile phase (acetonitrile-0.01 M phosphate buffer pH 3.5, 35:65), and an aliquot of 20 microliters was chromatographed on a Spherisorb ODS reversed-phase column. Quantitation was achieved by monitoring the ultraviolet absorbance at 275 nm. The response was linear (0-1000 ng/ml) and the detection limit was 5-10 ng/ml in plasma or urine. The within-assay variation was less than or equal to 10%. No interferences from metabolites or endogenous constituents were observed. The utility of the assay was demonstrated by determining glipizide in samples from a diabetic subject receiving a therapeutic dose of 5 mg of the drug.
已开发出一种灵敏且具选择性的高效液相色谱法,用于测定人血浆或尿液中的完整格列吡嗪。在加入甲苯磺丁脲作为内标之前,将血浆和尿液样品用酸性缓冲液处理。样品用苯萃取,有机层蒸发至干。残渣溶于平衡后的流动相(乙腈 - 0.01 M pH 3.5 的磷酸盐缓冲液,35:65),取 20 微升等分试样在 Spherisorb ODS 反相柱上进行色谱分析。通过监测 275 nm 处的紫外吸光度进行定量。响应呈线性(0 - 1000 ng/ml),血浆或尿液中的检测限为 5 - 10 ng/ml。批内变异小于或等于 10%。未观察到代谢物或内源性成分的干扰。通过测定接受 5 mg 该药物治疗剂量的糖尿病患者样品中的格列吡嗪,证明了该测定方法的实用性。